Journal of Enzyme Inhibition and Medicinal Chemistry (Dec 2023)

Synthesis and biological evaluation of C-4 substituted phenoxazine-bearing hydroxamic acids with potent class II histone deacetylase inhibitory activities

  • Jung-Chun Chu,
  • Hui-Ju Tseng,
  • Sung-Bau Lee,
  • Kai-Cheng Hsu,
  • Ling-Wei Hsin,
  • Ru-Hao Liang,
  • Tony Eight Lin,
  • Nain-Chu Gao,
  • Liang-Chieh Chen,
  • Wan-Hsun Lu,
  • Andrew H.-J Wang,
  • Wei-Jan Huang

DOI
https://doi.org/10.1080/14756366.2023.2212326
Journal volume & issue
Vol. 38, no. 1

Abstract

Read online

AbstractClass II histone deacetylases (HDACs) are considered as potential targets to treat Alzheimer’s disease (AD). Previously, C-3 substituted phenothiazine-containing compounds with class II HDAC-inhibiting activities was found to promote neurite outgrowth. This study replaced phenothiazine moiety with phenoxazine that contains many C-3 and C-4 substituents. Some resulting compounds bearing the C-4 substituent on a phenoxazine ring displayed potent class II HDAC inhibitory activities. Structure-activity relationship (SAR) of these compounds that inhibited HDAC isoenzymes was disclosed. Molecular modelling analysis demonstrates that the potent activities of C-4 substituted compounds probably arise from π-π stacked interactions between these compounds and class IIa HDAC enzymes. One of these, compound 7d exhibited the most potent class II HDAC inhibition (IC50= 3–870 nM). Notably, it protected neuron cells from H2O2-induced neuron damage at sub-μM concentrations, but with no significant cytotoxicity. These findings show that compound 7d is a lead compound for further development of anti-neurodegenerative agents.

Keywords